ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2416

The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort

Romina Nieto1, Rosana Quintana2, Diana Carolina Fernández Ávila3, Rosa Serrano Morales4, Guillermina Harvey5, Lucia Hernandez6, Karen Roberts7, Luis Catoggio8, Gisela Subils9, Carla Gobbi10, Bordón Florencia Juliana11, Pablo David Ibáñez Peña12, Leonel Ariel Berbotto13, María C. Bertolaccini14, Diego O. Riseni15, María De Los Ángeles Gargiulo16, Cecilia Pisoni17, Joaquín Martínez Serventi18, Emilio Buschiazzo19, Vitalina De Souza Barbosa20, ODIRLEI MONTICIELO21, Carolina Albanez de A. Da C. Andrade22, Francinne Machado Ribeiro23, Eloisa Bonfa24, Eduardo Borba24, Emília Sato25, Alexis Bondi Peralta26, Silvana Donoso27, Gustavo Aroca Martínez28, Hellen Medina28, Alex Echeverri29, Sebastián Molina-Rios30, Manuela Rubio31, Rafael López32, Mario Moreno33, Olga Lidia Vera Lastra34, Mario Pérez Cristóbal35, Carlos Núñez-Álvarez36, luis M Amezcua Guerra37, Ignacio García-Valladares38, Carlos Abud Mendoza39, Dionicio Galarza-Delgado40, Marcos Vázquez41, Astrid Paats42, Jorge N. Cieza Calderón43, Ana Mabel Quiroz Alva44, Roberto Muñoz Louis45, Carina Pizzarossa46, Adriana Carlomagno47 RV Gamboa-Cardenas48, Graciela Alarcon49, Urbano Sbarigia50, Federico Zazzetti51, Ashley Orillion52, Guillermo Pons-Estel1 and Bernardo Pons-Estel1, 1Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 3Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, 4Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, 5Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, 6Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, 7Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;, Buenos Aires, Argentina, 9Hospital Italiano de Córdoba, Córdoba, Argentina, Córdoba, Argentina, 10Hospital Córdoba, Ciudad de Córdoba, Argentina, Córdoba, Argentina, 11Hospital Privado Universitario de Córdoba, Córdoba, Argentina, 12Hospital HIGA San Martín, La Plata, Argentina, La Plata, Argentina, 13Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, 14Hospital Padilla, Tucumán, Argentina, Tucumán, Argentina, 15Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, Buenos Aires, Argentina, 16Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, Buenos Aires, Argentina, 17CEMIC, Buenos Aires, Argentina, 18Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, CABA, Argentina, 19Hospital Señor del Milagro, Salta, Argentina, Salta, Argentina, 20Hospital das Clínicas, Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, 21HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, 22Universidade Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, 23Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, 24Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 25Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, 26Hospital del Salvador, Santiago, Chile, 27Clinical Laboratory Hospital Regional Libertador Bernardo O'Higgins, Rancagua, Chile, Rancagua, Chile, 28Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, 29Fundación Valle del Lili, Unidad de Reumatología, Colombia, Reumatología, Colombia, 30Facultad de Medicina, Universidad Nacional de Colombia. Hospital Universitario Nacional, Bogotá, Colombia, 31Centro de Estudios de Reumatología & Dermatología SAS, Bogotá, Colombia, 32Servicio de Reumatología. Hospital Luís Vernaza, Guayaquil, Ecuador, Guayaquil, Ecuador, 33Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, 34División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, 35Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, 36Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, 37Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, 38Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, Guadalajara, Mexico, 39Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, 40UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 41Hospital de Clínicas I, Asunción, Paraguay, Asuncion del Paraguay, Paraguay, 42Hospital de Clínicas I, Asunción, Paraguay, 43Hospital Nacional Edgardo Rebagliatti Martins, Lima, Perú, Lima, Peru, 44Hospital Cayetano Heredia, Lima, Perú, Lima, Peru, 45Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, 46Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, 47Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, 48Universidad Científica del Sur, Lima, Lima, Peru, 49The University of Alabama at Birmingham, Birmingham, AL, 50Johnson & Johnson Innovative Medicine, Brussels, Belgium, 51Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 52Johnson & Johnson Innovative Medicine, Spring House, PA

Meeting: ACR Convergence 2024

Keywords: Lupus nephritis, Patient reported outcomes, Systemic lupus erythematosus (SLE), work

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus (SLE) in Latin-American countries. Here we evaluated the work productivity and activity impairment (WPAI) in patients with active lupus nephritis (LN) at cohort entry and 12 months after treatment initiation according to their renal response.

Methods: Forty-four centers from Latin-American countries enrolled patients ≥18 years of age who fulfilled the 1982/1997 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE. Patients from different subsets of LN were enrolled. For this analysis, patients in Group II (prevalent inactive LN), III (prevalent active LN), and IV (incident LN) and 12-month follow-up data were included. Demographic, clinical manifestations, disease activity (SLEDAI-2k) and damage SLICC/ACR Damage Index (SDI) were examined. At baseline, WPAI scores stratified by the presence of active or inactive LN were compared. At 12 months, absenteeism, presenteeism, global work impairment in employed patients and activity impairment in patients with active LN were compared according to their renal response. Renal responses were defined according to EULAR/Kidney Disease Improving Global Outcomes (KDIGO) – complete clinical response: urine protein creatinine ratio (UPCR) < 0.5 g/g; partial clinical response: ≥ 50% reduction in UPCR; no response: < 50% reduction in proteinuria. Descriptive analyses were performed.

Results: Of the 1081 patients included in the cohort, 651 with history of LN were evaluated (423 with active LN and 228 with inactive LN). Of the active LN patients, 369 (87.4%) were women, were younger at cohort entry, of a lower socioeconomic status, had a higher unemployment rate and a higher SLEDAI than patients with inactive LN. Of the LN patients, 257 (39.5%) were employed (salaried work) at cohort entry and were included in this analysis. Patients with active LN showed higher rates of impairment in the WPAI score with greater impact and lower work productivity in all domains than in patients with inactive LN (Table 1). At 12 months, there was no evidence of a positive impact on work productivity as measured by the WPAI in patients who achieved renal response (Table 2).

Conclusion: Patients with active LN presented a greater impairment on WP compared to patients with inactive LN. There was no evidence of a positive impact on WP in patients who achieved a complete or partial renal response after 12 months of treatment. Future analyses with a larger number of patients being followed up would be necessary to provide more definitive data.

Supporting image 1

Table 1. Baseline Evaluation of Work Productivity with the WPAI in the GLADEL 2.0 SLE Cohort of Patients with Lupus Nephritis from Different Groups

Supporting image 2

Table 2. Evaluation of the Impact of Achieving Renal Response at 12 Months on WPAI in Patients with Active Lupus Nephritis


Disclosures: R. Nieto: None; R. Quintana: None; D. Ávila: None; R. Serrano Morales: None; G. Harvey: None; L. Hernandez: None; K. Roberts: None; L. Catoggio: None; G. Subils: None; C. Gobbi: None; B. Juliana: None; P. Ibáñez Peña: None; L. Ariel Berbotto: None; M. Bertolaccini: None; D. Riseni: None; M. De Los Ángeles Gargiulo: None; C. Pisoni: None; J. Serventi: None; E. Buschiazzo: None; V. De Souza Barbosa: None; O. MONTICIELO: AbbVie/Abbott, 6, AstraZeneca, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, UCB, 6; C. Andrade: None; F. Ribeiro: None; E. Bonfa: GlaxoSmithKlein(GSK), 5; E. Borba: None; E. Sato: None; A. Peralta: None; S. Donoso: None; G. Aroca Martínez: None; H. Medina: None; A. Echeverri: None; S. Molina-Rios: None; M. Rubio: None; R. López: None; M. Moreno: None; O. Vera Lastra: None; M. Pérez Cristóbal: None; C. Núñez-Álvarez: None; l. Amezcua Guerra: None; I. García-Valladares: None; C. Mendoza: None; D. Galarza-Delgado: None; M. Vázquez: None; A. Paats: None; J. Calderón: None; A. Alva: None; R. Louis: None; C. Pizzarossa: None; A. Carlomagno: None; R. Gamboa-Cardenas: None; G. Alarcon: None; U. Sbarigia: Janssen, 3, Johnson & Johnson, 11; F. Zazzetti: Janssen, 3, Johnson & Johnson, 11; A. Orillion: Janssen, 3, Johnson & Johnson, 11; G. Pons-Estel: Abbvie, 6, AstraZeneca, 1, 6, 12, Support to attend a scientific event, Boehringer-Ingelheim, 1, 2, 6, 12, Support to attend a scientific event, GSK, 1, 5, 6, Janssen, 1, 5, 6, Novartis, 1, 6, 12, Support to attend a scientific event, Pfizer, 1, 6, Remegen, 1, RemeGen, 1, 2, Remegen, 2, RemeGen, 5, 6, Remegen, 6, Sanofi, 1, 2, 5, 6, Werfen Diagnostics, 1, 2, 5, 6; B. Pons-Estel: AstraZeneca, 1, 6, GSK, 1, 6, Janssen, 1, 6.

To cite this abstract in AMA style:

Nieto R, Quintana R, Ávila D, Serrano Morales R, Harvey G, Hernandez L, Roberts K, Catoggio L, Subils G, Gobbi C, Juliana B, Ibáñez Peña P, Ariel Berbotto L, Bertolaccini M, Riseni D, De Los Ángeles Gargiulo M, Pisoni C, Serventi J, Buschiazzo E, De Souza Barbosa V, MONTICIELO O, Andrade C, Ribeiro F, Bonfa E, Borba E, Sato E, Peralta A, Donoso S, Aroca Martínez G, Medina H, Echeverri A, Molina-Rios S, Rubio M, López R, Moreno M, Vera Lastra O, Pérez Cristóbal M, Núñez-Álvarez C, Amezcua Guerra l, García-Valladares I, Mendoza C, Galarza-Delgado D, Vázquez M, Paats A, Calderón J, Alva A, Louis R, Pizzarossa C, Carlomagno A, Gamboa-Cardenas R, Alarcon G, Sbarigia U, Zazzetti F, Orillion A, Pons-Estel G, Pons-Estel B. The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-active-lupus-nephritis-on-work-productivity-in-patients-from-a-latin-american-lupus-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-active-lupus-nephritis-on-work-productivity-in-patients-from-a-latin-american-lupus-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology